GREENVILLE, S.C. and SACRAMENTO, Calif., Jan. 6, 2026 /PRNewswire/ — PAI Pharma (“PAI”), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturerGREENVILLE, S.C. and SACRAMENTO, Calif., Jan. 6, 2026 /PRNewswire/ — PAI Pharma (“PAI”), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer

PAI Pharma Acquires Nivagen Pharmaceuticals, Expanding Domestic Sterile Injectable Manufacturing and Expanding Ready-To-Use (“RTU”) Product Offering in the Hospital Market

2026/01/07 03:01
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

GREENVILLE, S.C. and SACRAMENTO, Calif., Jan. 6, 2026 /PRNewswire/ — PAI Pharma (“PAI”), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer and marketer of oral liquid medicines, today announced the acquisition of Nivagen Pharmaceuticals, Inc. (“Nivagen”), a California-based pharmaceutical company with advanced aseptic manufacturing infrastructure and a robust pipeline of ready-to-use sterile injectables.  The acquisition marks a significant step forward in PAI’s strategy to expand domestic pharmaceutical manufacturing, strengthen supply-chain resilience, and accelerate growth in RTU sterile injectable and hospital-focused therapies, areas that continue to face persistent drug shortages across the U.S. healthcare system.

Nivagen operates a newly built, state-of-the-art aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes, and cartridges. Nivagen brings a rich pipeline of over 20 RTU injectable products, which complements PAI’s existing sterile portfolio of approximately 10 products currently in development and 4 on the market. The combined pipeline positions PAI to better serve hospitals and health systems with high-quality, domestically manufactured sterile therapies.

“PAI is a market leader in RTU oral liquid medicines, and that same focus on quality, reliability, and patient-centric design carries naturally into RTU injectables,” said Kurt Orlofski, CEO of PAI Pharma.

“Olympus is proud to continue supporting PAI as it expands into sterile injectables,” said Griffin Barstis, Partner at Olympus Partners. “We believe the combination of PAI’s leadership in RTU oral liquids and Nivagen’s injectable platform creates a unique business that is well-positioned to serve hospitals and healthcare providers with critical, high-quality medicines.”

Strengthening Domestic Manufacturing and Addressing Drug Shortages

The transaction aligns with growing national focus on reshoring pharmaceutical production, reducing reliance on foreign supply chains, and ensuring consistent access to essential medicines. Aseptic sterile products, particularly RTU injectables, remain among the most shortage-prone therapies in the U.S., underscoring the need for increased domestic capacity and long-term investment. Industry stakeholders and policy leaders have increasingly emphasized that economic resilience, national health security, and patient access depend on sustained investment in U.S. manufacturing, skilled labor, and advanced production capabilities — priorities directly supported by this acquisition.

“This acquisition represents a meaningful investment in American pharmaceutical manufacturing at a time when domestic capacity, reliability, and readiness matter more than ever,” said Jay Shukla, President of Nivagen Pharmaceuticals.

“This investment underscores the growing role Natomas and the Sacramento region are playing in strengthening America’s pharmaceutical manufacturing capacity,” said Congressman Ami Bera, M.D. (CA-06). “This state-of-the-art facility is helping expand access to ready-to-use sterile injectable medicines, support hospital systems, and improve patient care. I appreciate PAI’s investment and look forward to working with them to position the Sacramento region for further growth.”

Advisors

PAI Pharma and Olympus Partners were advised by Bourne Partners, Kirkland & Ellis LLP as legal counsel, and KPMG LLP as financial and accounting advisor.

About PAI Pharma

PAI Pharma is a U.S.-based pharmaceutical manufacturer specializing in oral liquid generic prescription medications, with a strong domestic manufacturing footprint and a commitment to quality, affordability, and supply chain resilience. In addition to its oral liquid manufacturing operations, PAI also distributes a portfolio of sterile injectable medications, expanding patient access to critical therapies across care settings. With more than five decades of experience, PAI plays a vital role in supporting the reliability of the U.S. pharmaceutical supply chain.

About Olympus Partners

Olympus Partners is a private equity firm focused on providing equity capital for middle market management buyouts and for growing companies. Olympus manages in excess of $12 billion mainly on behalf of corporate pension funds, endowment funds and state-sponsored retirement programs. Founded in 1988, Olympus is an active, long-term investor across a broad range of industries including healthcare, business services, food services, consumer products, financial services, industrial services and manufacturing.

About Nivagen Pharmaceuticals

Founded in 2009 and headquartered in Sacramento, California, Nivagen Pharmaceuticals, Inc. is a specialty pharmaceutical company with advanced aseptic manufacturing infrastructure and a pipeline focused on ready-to-use sterile injectables and complex dosage forms.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pai-pharma-acquires-nivagen-pharmaceuticals-expanding-domestic-sterile-injectable-manufacturing-and-expanding-ready-to-use-rtu-product-offering-in-the-hospital-market-302654196.html

SOURCE PAI Pharma

Market Opportunity
ParallelAI Logo
ParallelAI Price(PAI)
$0.006223
$0.006223$0.006223
-3.87%
USD
ParallelAI (PAI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

USDH Power Struggle Ignites Stablecoin “Bidding Wars” Across DeFi: Bloomberg

A heated contest for control over a new dollar-pegged token has set the stage for what analysts say could define the next phase of the stablecoin industry. According to Bloomberg, a bidding war unfolded on Hyperliquid, one of crypto’s fastest-growing trading platforms, with the prize being the right to issue USDH, its native stablecoin. The competition drew some of the sector’s most prominent names, including Paxos, Sky, and Ethena, who later withdrew their bid, alongside the lesser-known Native Markets, a startup backed by Stripe stablecoin subsidiary Bridge. Hyperliquid Stablecoin Race Shows Branding and Partnerships Matter as Much as Tech Over the weekend, Hyperliquid’s validators, the contributors who secure the network and vote on key decisions, awarded the USDH contract to Native Markets over the weekend. Despite its relatively new status, the firm’s connection with Stripe helped it outpace more established rivals. Stablecoins underpin decentralized finance by providing a dollar-backed medium for collateral, settlement, and payments across applications. What began as a grassroots, community-led sector has evolved into a battleground for institutions and payment companies seeking revenue from interest on reserves. Circle, for example, shares proceeds from its USDC with Coinbase under a partnership designed to stabilize earnings during market swings. The Hyperliquid contest offered a rare glimpse into just how intense competition has become. Paxos pledged to take no revenue until USDH surpassed $1 billion in circulation. Agora offered to share 100% of net revenue with Hyperliquid, while Ethena put forward 95%. All were outbid by Native Markets, whose ties to Stripe’s $1.1 billion acquisition of Bridge and subsequent rollout of the Tempo blockchain positioned it as a strong contender. “Every stablecoin issuer is extremely desperate for supply,” said Zaheer Ebtikar, co-founder of Split Capital. “They are willing to publicly announce how much they are willing to offer. It just shows it’s a very tough business for stablecoin issuers.” While USDC remains dominant on Hyperliquid with more than $5.6 billion in deposits, the arrival of USDH could shift flows and revenue dynamics. Paxos co-founder Bhau Kotecha said the firm sees the exchange’s growth as an important opportunity, while Agora’s co-founder Nick van Eck warned that awarding the contract to a vertically integrated issuer risked undermining decentralization. Regulatory positioning also factored into the debate. Paxos operates under a New York trust charter and is seeking a federal license, while Bridge holds money transmitter approvals in 30 states. Native Markets, in a blog post, cited regulatory flexibility and deployment speed as reasons for its selection. Hyperliquid said the strong engagement from its community validated the process. Circle CEO Jeremy Allaire dismissed concerns over USDC’s status, noting on X that competition benefits the ecosystem. Analysts suggested that fears of centralization may be exaggerated, noting that Hyperliquid is likely to remain neutral and support multiple stablecoins. Still, the contest over USDH highlighted a new reality for stablecoins: branding, partnerships, and business strategy are becoming as decisive as technology. Native Markets Secures USDH Stablecoin Mandate on Hyperliquid Hyperliquid has concluded its governance vote for the USDH stablecoin, awarding the mandate to Native Markets after a closely watched process that drew weeks of community debate and rival proposals. USDH, described by Hyperliquid as a “Hyperliquid-first, compliant, and natively minted” dollar-backed token, is intended to reduce the platform’s dependence on USDC and strengthen its spot markets. Validators on the decentralized exchange voted in favor of Native Markets, a relatively new player backed by Stripe’s Bridge subsidiary, over established contenders including Paxos and Ethena. The outcome followed a string of proposals offering aggressive revenue-sharing terms to win validator support, underscoring the scale of incentives attached to controlling USDH. Hyperliquid’s exchange has become a critical hub for stablecoin liquidity, with $5.7 billion in USDC, around 8% of its total supply, currently held on the network. At prevailing treasury yields, that translates to an estimated $200 million to $220 million in annual revenue for Circle, underlining why a native alternative could be transformative. Hyperliquid’s validators, who secure the network and vote on key decisions, selected Native Markets following an on-chain governance process that concluded September 15. Native Markets has laid out a phased rollout for USDH, beginning with capped minting and redemption trials before expanding into spot markets. Its reserves will be managed in cash and treasuries by BlackRock, with on-chain tokenization through Superstate and Bridge. Yield from those reserves will be split between Hyperliquid’s Assistance Fund and ecosystem development. The launch of USDH comes as Hyperliquid records record profits from perpetual futures trading, with $106 million in revenue in August alone, and prepares to slash spot trading fees by 80% to bolster liquidity. Analysts say the move positions Hyperliquid to capture more of the stablecoin economics internally, marking a significant step in its bid to rival the largest players in decentralized finance
Share
CryptoNews2025/09/18 00:48
Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

Bitcoin Market Faces Renewed Pressure: What Lies Ahead?

The post Bitcoin Market Faces Renewed Pressure: What Lies Ahead? appeared on BitcoinEthereumNews.com. Recent data reveals heightened instability in the cryptocurrency
Share
BitcoinEthereumNews2026/03/31 01:21
BTC fell below $67,000, down 0.94% on the day.

BTC fell below $67,000, down 0.94% on the day.

PANews reported on March 31 that, according to OKX market data, BTC has just fallen below $67,000 and is currently trading at $66,989.20 per coin, down 0.94% on
Share
PANews2026/03/31 01:22